Ethanol consumption by Fawn-Hooded rats following abstinence:: Effect of naltrexone and changes in μ-opioid receptor density

被引:39
作者
Cowen, MS [1 ]
Rezvani, AH
Jarrott, B
Lawrence, AJ
机构
[1] Monash Univ, Dept Pharmacol, Clayton, Vic 3168, Australia
[2] Univ N Carolina, Sch Med, Skipper Bowles Ctr Alcohol Studies, Chapel Hill, NC 27599 USA
关键词
ethanol; alcohol deprivation effect; mu-opioid receptor; Fawn-Hooded rat;
D O I
10.1097/00000374-199906000-00007
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Relapse after abstinence can be modelled in rats using an alcohol deprivation effect (ADE) of enhanced ethanol consumption after a period of enforced abstinence from ethanol; however, not all rat strains display such an effect. We wanted to examine the effect of naltrexone on ethanol consumption by ethanol-preferring Fawn-Hooded (FH) rats using such a model. Methods: FH rats were given continual free-choice access to a 5% ethanol solution or water (4 weeks) followed by 2 weeks of water alone. At the end of this abstinence period, osmotic minipumps were implanted subcutaneously to deliver saline (n = 4) or naltrexone (n = 4; 8.4 mg/kg/day for 4 weeks). After recovery from surgery, the rats were again given access to 5% ethanol under the same free-choice conditions (4 weeks). A third group of age-matched controls drank only water during the behavioral trial. At the end of the behavioral trial, the rats were decapitated and an autoradiographic examination was made of mu-opioid receptor density through the forebrain using the ligand [I-125]FK-33824. Results: First, a period of enforced abstinence from ethanol consumption caused a significant (p < 0.05) and prolonged increase in ethanol preference (+18%) and decrease in water consumption (-53%), although the volume of ethanol consumed (ml/day) did not vary, indicating an atypical ADE in this rat strain. Second, naltrexone significantly (p < 0.05) decreased ethanol consumption by the FH rats in terms of absolute amount of ethanol consumed and preference for ethanol solution, but this effect of naltrexone diminished over time, concurrent with a robust and significant elevation in mu-opioid receptor density in all brain regions examined (p < 0.05). Finally, ethanol consumption alone also upregulated mu-opioid receptor density relative to nondrinking controls in a number of brain regions, which included the nucleus accumbens (+29%) and caudate-putamen (+15%, p < 0.05), but decreased mu-opioid receptor density in other regions including the substantia nigra pars reticulata, which was suggestive of an indirect effect on mu-opioid receptors. Conclusions: The data suggest that continual long-term naltrexone treatment may not be effective in the treatment of alcoholism, possibly because of the induced increase in mu-opioid receptor density.
引用
收藏
页码:1008 / 1014
页数:7
相关论文
共 69 条
[1]   ALTERATION OF ETHANOL SELF-ADMINISTRATION BY NALTREXONE [J].
ALTSHULER, HL ;
PHILLIPS, PE ;
FEINHANDLER, DA .
LIFE SCIENCES, 1980, 26 (09) :679-688
[2]   Effect of pentylenetetrazole on ethanol intake, ethanol kinetics, and social behavior in male Wistar rats [J].
Buczek, Y ;
Lê, AD ;
Sellers, EM ;
Tomkins, DM .
ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 1998, 22 (02) :428-436
[3]  
BUNZOW JR, 1995, J NEUROCHEM, V64, P14
[4]  
CHARNESS ME, 1993, MOL PHARMACOL, V44, P1119
[5]   Distribution of GABAA receptors in the limbic system of alcohol-preferring and non-preferring rats:: in situ hybridisation histochemistry and receptor autoradiography [J].
Chen, F ;
Rezvani, A ;
Jarrott, B ;
Lawrence, AJ .
NEUROCHEMISTRY INTERNATIONAL, 1998, 32 (02) :143-151
[6]  
CHEN Y, 1993, MOL PHARMACOL, V44, P8
[7]  
CHIZZONITE R, 1991, J IMMUNOL, V147, P1548
[8]  
Cowen M. S., 1998, Alcoholism Clinical and Experimental Research, V22, p177A
[9]   Distribution of opioid peptide gene expression in the limbic system of Fawn-Hooded (alcohol-preferring) and Wistar-Kyoto (alcohol-non-preferring) rats [J].
Cowen, MS ;
Rezvani, A ;
Jarrott, B ;
Lawrence, AJ .
BRAIN RESEARCH, 1998, 796 (1-2) :323-326
[10]  
Crews F. T., 1998, Alcoholism Clinical and Experimental Research, V22, p177A